Laurus Labs Ltd

Laurus Labs Ltd

₹ 571 0.61%
26 Dec - close price
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Integrated Pharma Company[1] Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth therapeutic areas and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.

  • Market Cap 30,764 Cr.
  • Current Price 571
  • High / Low 593 / 359
  • Stock P/E 131
  • Book Value 79.2
  • Dividend Yield 0.14 %
  • ROCE 7.50 %
  • ROE 5.43 %
  • Face Value 2.00

Pros

Cons

  • Stock is trading at 7.21 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
1,176 933 1,378 1,495 1,498 1,501 1,279 1,108 1,158 1,132 1,415 1,117 1,185
842 717 1,005 1,077 1,072 1,116 1,027 980 978 962 1,143 956 1,003
Operating Profit 334 215 373 418 426 385 252 128 181 170 271 161 182
OPM % 28% 23% 27% 28% 28% 26% 20% 12% 16% 15% 19% 14% 15%
4 7 2 3 4 3 6 7 6 11 24 9 12
Interest 21 21 29 28 38 39 41 33 38 38 42 41 45
Depreciation 59 60 61 66 76 78 81 84 85 87 89 91 91
Profit before tax 258 142 285 328 317 270 137 17 63 57 164 39 58
Tax % 24% 23% 22% 29% 28% 26% 25% 24% 26% 25% 26% 26% 27%
198 109 221 232 227 199 102 13 47 43 121 29 42
EPS in Rs 3.68 2.03 4.12 4.31 4.23 3.70 1.90 0.24 0.87 0.79 2.25 0.53 0.79
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
719 1,160 1,326 1,775 1,892 2,027 2,236 2,797 4,769 4,707 5,773 4,812 4,848
573 951 1,121 1,402 1,478 1,618 1,884 2,226 3,258 3,421 4,292 4,062 4,064
Operating Profit 145 209 205 372 414 409 352 571 1,511 1,286 1,482 751 785
OPM % 20% 18% 15% 21% 22% 20% 16% 20% 32% 27% 26% 16% 16%
5 9 34 4 32 28 15 5 26 20 16 47 56
Interest 41 64 106 111 97 75 86 88 66 96 146 151 165
Depreciation 23 33 61 86 104 121 161 184 197 235 301 345 358
Profit before tax 86 121 72 180 245 241 121 304 1,275 975 1,051 301 318
Tax % -2% 20% -2% 19% 18% 28% 22% 12% 25% 23% 28% 26%
88 97 74 145 200 173 95 267 956 750 760 224 235
EPS in Rs 11.58 12.64 9.47 18.36 3.78 3.27 1.78 5.00 17.82 13.96 14.12 4.15 4.36
Dividend Payout % 0% 0% 0% 2% 8% 9% 17% 10% 11% 14% 14% 19%
Compounded Sales Growth
10 Years: 15%
5 Years: 17%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 9%
5 Years: 19%
3 Years: -38%
TTM: -35%
Stock Price CAGR
10 Years: %
5 Years: 51%
3 Years: 3%
1 Year: 32%
Return on Equity
10 Years: 18%
5 Years: 20%
3 Years: 16%
Last Year: 5%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 15 15 16 16 106 106 106 107 107 107 108 108 108
Reserves 182 281 645 790 1,250 1,407 1,484 1,709 2,605 3,281 3,949 4,099 4,162
355 605 888 1,081 808 947 1,009 1,051 1,411 1,653 1,714 2,110 2,341
150 372 344 342 509 547 718 872 1,502 1,567 1,187 1,351 1,478
Total Liabilities 701 1,273 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,667 8,088
236 499 801 1,014 1,193 1,448 1,599 1,694 1,818 2,186 2,884 3,036 2,906
CWIP 73 116 107 70 143 163 107 67 324 755 357 156 255
Investments 0 0 19 26 51 52 58 58 319 362 384 635 635
393 658 966 1,119 1,286 1,345 1,554 1,920 3,164 3,306 3,333 3,841 4,292
Total Assets 701 1,273 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,667 8,088

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
88 121 -59 197 321 369 293 345 694 823 882 659
-124 -312 -406 -315 -282 -417 -257 -217 -900 -837 -735 -757
34 203 486 90 -47 49 -37 -127 243 15 -185 139
Net Cash Flow -2 12 21 -27 -8 0 -0 0 38 2 -39 41

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 80 61 78 91 108 100 112 102 98 98 94 124
Inventory Days 138 165 210 177 184 199 201 233 257 279 211 258
Days Payable 117 114 101 91 110 106 144 157 194 140 90 151
Cash Conversion Cycle 101 112 187 177 183 193 169 177 161 237 216 231
Working Capital Days 93 48 119 117 126 124 116 119 127 140 138 175
ROCE % 27% 25% 15% 17% 17% 14% 8% 14% 38% 23% 22% 8%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
27.27% 27.27% 27.27% 27.27% 27.20% 27.20% 27.20% 27.20% 27.18% 27.18% 27.18% 27.18%
22.08% 22.45% 21.98% 22.67% 21.90% 22.42% 22.52% 24.03% 25.39% 25.98% 25.67% 26.08%
6.90% 7.93% 9.11% 9.34% 9.51% 9.74% 10.36% 11.01% 11.13% 11.78% 13.56% 13.05%
43.76% 42.36% 41.65% 40.74% 41.38% 40.64% 39.93% 37.75% 36.30% 35.07% 33.59% 33.69%
No. of Shareholders 4,67,4194,27,4654,07,1863,90,6954,23,9314,18,6154,17,9774,02,6403,82,8803,56,8303,24,0593,09,063

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls